SFNEP oncology nutrition guidelines: Appetite stimulants and anti-cachexia treatment;Nutrition chez le patient adulte atteint de cancer: Orexigènes et autres médicaments anticachectisants

Nutrition Clinique et Metabolisme

Volumn 26, Issue 4, 2012, Pages 269-277

  Crenn, Pascal ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APPETITE STIMULANT; NUTRACEUTICAL;

APPETITE; ARTICLE; CACHEXIA; DIET SUPPLEMENTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NUTRITION; NUTRITIONAL SUPPORT; PRACTICE GUIDELINE;

EID: 84870728453     PISSN: 09850562     EISSN: 17683092     Source Type: Journal    
DOI: 10.1016/j.nupar.2012.10.010     Document Type: Article

References (45)

1. Tchekmedyian N.S., Halpert C., Ashley J., Heber D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr 1992, 16(6 Suppl.):88S-92S.
2. Ramos E.J., Suzuki S., Marks D., Inui A., Asakawa A., Meguid M.M. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004, 7(4):427-434.
3. Desport J.C., Blanc-Vincent M.P., Gory-Delabaere G., Bachmann P., Beal J., Benamouzig R., et al. Standards, options and recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC). Bull Cancer 2000, 87(4):315-328.
4. Desport J.C., Gory-Delabaere G., Blanc-Vincent M.P., Bachmann P., Beal J., Benamouzig R., et al. Standards, options and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer 2003, 89(Suppl. 1):S98-S100.
5. Yavuzsen T., Davis M.P., Walsh D., LeGrand S., Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005, 23(33):8500-8511.
6. Moertel C.G., Schutt A.J., Reitemeier R.J., Hahn R.G. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974, 33(6):1607-1609.
7. Willox J.C., Corr J., Shaw J., Richardson M., Calman K.C., Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984, 288(6410):27.
8. Bruera E., Roca E., Cedaro L., Carraro S., Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985, 69(7-8):751-754.
9. Popiela T., Lucchi R., Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989, 25(12):1823-1829.
10. Della Cuna G.R., Pellegrini A., Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989, 25(12):1817-1821.
11. Lai Y.L., Fang F.M., Yeh C.Y. Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. J Pain Symptom Manage 1994, 9(4):265-268.
12. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., Krook J.E., Wilwerding M.B., et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999, 17(10):3299-3306.
13. Sarcev T., Secen N., Sabo A., Povazan D. Influence of dexamethasone on appetite and body weight in lung cancer patients. Med Pregl 2008, 61(11-12):571-575.
14. Jeanfaivre T., Souday V., Chaleil D., Maillet F., Tuchais E. Phase II trial evaluating the effect of megestrol acetate-prednisolone combination in the treatment of anorexia during the palliative-care phase of lung cancer. Rev Pneumol Clin 2000, 56(4):255-260.
15. Maltoni M., Nanni O., Scarpi E., Rossi D., Serra P., Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001, 12(3):289-300.
16. Tchekmedyian N.S., Hickman M., Siau J., Greco F.A., Keller J., Browder H., et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992, 69(5):1268-1274.
17. Simons J.P., Aaronson N.K., Vansteenkiste J.F., ten Velde G.P., Muller M.J., Drenth B.M., et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996, 14(4):1077-1084.
18. Mantovani G., Maccio A., Madeddu C., Gramignano G., Serpe R., Massa E., et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008, 24(4):305-313.
19. Jatoi A., Windschitl H.E., Loprinzi C.L., Sloan J.A., Dakhil S.R., Mailliard J.A., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002, 20(2):567-573.
20. Ulutin H.C., Arpaci F., Pak Y. Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori 2002, 88(4):277-280.
21. Navari R.M., Brenner M.C. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010, 18(8):951-956.
22. Jatoi A., Rowland K., Loprinzi C.L., Sloan J.A., Dakhil S.R., MacDonald N., et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004, 22(12):2469-2476.
23. McQuellon R.P., Moose D.B., Russell G.B., Case L.D., Greven K., Stevens M., et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2002, 52(5):1180-1185.
24. Pascual Lopez A., Roque i Figuls M., Urrutia Cuchi G., Berenstein E.G., Almenar Pasies B., Balcells Alegre M., et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004, 27(4):360-369.
25. Berenstein E.G., Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005, (2). CD004310.
26. Westman G., Bergman B., Albertsson M., Kadar L., Gustavsson G., Thaning L., et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. Eur J Cancer 1999, 35(4):586-595.
27. Tomiska M., Tomiskova M., Salajka F., Adam Z., Vorlicek J. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003, 50(3):227-233.
28. Downer S., Joel S., Allbright A., Plant H., Stubbs L., Talbot D., et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993, 67(5):1102-1105.
29. Simons J.P., Schols A.M., Hoefnagels J.M., Westerterp K.R., ten Velde G.P., Wouters E.F. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 1998, 82(3):553-560.
30. Cerchietti L.C., Navigante A.H., Peluffo G.D., Diament M.J., Stillitani I., Klein S.A., et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 2004, 27(1):85-95.
31. Goldberg R.M., Loprinzi C.L., Mailliard J.A., O'Fallon J.R., Krook J.E., Ghosh C., et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995, 13(11):2856-2859.
32. Chlebowski R.T., Herrold J., Ali I., Oktay E., Chlebowski J.S., Ponce A.T., et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986, 58(1):183-186.
33. Nelson K., Walsh D., Deeter P., Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994, 10(1):14-18.
34. Strasser F., Luftner D., Possinger K., Ernst G., Ruhstaller T., Meissner W., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006, 24(21):3394-3400.
35. Jatoi A., Dakhil S.R., Nguyen P.L., Sloan J.A., Kugler J.W., Rowland K.M., et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007, 110(6):1396-1403.
36. Jatoi A., Ritter H.L., Dueck A., Nguyen P.L., Nikcevich D.A., Luyun R.F., et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010, 68(2):234-239.
37. Riechelmann R.P., Burman D., Tannock I.F., Rodin G., Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care 2010, 27(2):106-110.
38. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., Goggin P.M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005, 54(4):540-545.
39. Wilson J., Plourde J.Y., Marshall D., Yoshida S., Chow W., Harsanyi Z., et al. Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. J Palliat Care 2002, 18(2):84-91.
40. Persson C., Glimelius B., Ronnelid J., Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 2005, 21(2):170-178.
41. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89(6):2832-2836.
42. Strasser F., Lutz T.A., Maeder M.T., Thuerlimann B., Bueche D., Tschop M., et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008, 98(2):300-308.
43. Kardinal C.G., Loprinzi C.L., Schaid D.J., Hass A.C., Dose A.M., Athmann L.M., et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65(12):2657-2662.
44. Couluris M., Mayer J.L., Freyer D.R., Sandler E., Xu P., Krischer J.P. The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia. J Pediatr Hematol Oncol 2008, 30(11):791-797.
45. Jatoi A., Jett J.R., Sloan J., Novotny P., Ford J., Prabhakar U., et al. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients. Support Care Cancer 2004, 12(12):859-863.